WO1997017953A1 - Procede pour traiter, prevenir ou minimiser la perte des cheveux au moyen d'une source d'acides gras - Google Patents

Procede pour traiter, prevenir ou minimiser la perte des cheveux au moyen d'une source d'acides gras Download PDF

Info

Publication number
WO1997017953A1
WO1997017953A1 PCT/US1996/018143 US9618143W WO9717953A1 WO 1997017953 A1 WO1997017953 A1 WO 1997017953A1 US 9618143 W US9618143 W US 9618143W WO 9717953 A1 WO9717953 A1 WO 9717953A1
Authority
WO
WIPO (PCT)
Prior art keywords
source
alopecia
fatty acid
hair
treatment
Prior art date
Application number
PCT/US1996/018143
Other languages
English (en)
Inventor
Wen G. Chen
Maria Cifuentes
Stephen J. Galli
George C. Hwang
Alice Lin
Maureen H. Mcaloon
Karen A. Sanborn
Richard J. Sharpe
Zianbo Zhang
Original Assignee
Arcturus Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Pharmaceutical Corporation filed Critical Arcturus Pharmaceutical Corporation
Priority to AU76787/96A priority Critical patent/AU7678796A/en
Publication of WO1997017953A1 publication Critical patent/WO1997017953A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • This invention relates to a method for the treatment of alopecia (hair loss) by the topical administration of a fatty acid source.
  • Alopecia is generally divided into androgenetic alopecia, telogen effluvium (shed) , anagen effluvium, and alopecia areata.
  • the most common form of alopecia i ⁇ androgenetic alopecia.
  • Synonyms for this disorder include common baldness, hereditary baldness, male-pattern baldness, premature baldness, and diffuse alopecia.
  • It is a genetically determined form of gradual hair loss that begins as a receding hair line and/or thinning at the vertex (crest) of the scalp.
  • a gradual decrease in hair shaft length and diameter may eventually result in near total replacement of terminal hair with soft, short vellus hair.
  • a band of hair is usually retained along the peripheral scalp.
  • onset can begin as early as adolescence.
  • women the pattern is exhibited as thinning of the parietal and vertex regions, and the age of onset is usually two decades after the onset in men.
  • the utility of this treatment is modest at best .
  • approximately 25%, 7%, and 0.7% of patients achieve minimal, moderate and dense regrowth of hair, respectively.
  • the response appears to be more favorable in women and men under 40, in those who have been bald for less than 10 years, and when the affected area is less than 10 cm in diameter (Price, V.H., Rogaine in "The Management of Male- Pattern Baldness and Alopecia Areata", Proceedings of a Symposium, J. Am. Acad. Dermatol . , 1987, Vol. 16, pp. 749-750) .
  • Patients with severe hair loss are currently instructed that most therapeutic attempts to treat hair loss are ultimately unsuccessful, and physicians must simply help patients make the psychological adjustment to permanent hair loss.
  • Telogen effluvium is the second most common form of alopecia. It can be induced by such factors as childbirth, surgery, psychological stress, certain drugs, androgen excess, nutritional and metabolic disorders, autoimmune diseases, chronic infections, chronic scalp disease and chronic alopecia areata. Telogen effluvium usually affects less than 20 to 35 percent of the scalp hair, and occurs approximately 6 weeks to 3 months after a triggering event.
  • Anagen effluvium usually affects more than 80-90 percent of the total body hair, and begins 1 to 2 weeks after a triggering event.
  • Anagen effluvium can be caused by anti-coagulants, anti-metabolites, cytotoxic agents, alkylating agents, and alopecia areata, or by poisoning with lead, arsenic, mercury, thallium, and certain chemotherapeutic agents as well as ionizing radiation.
  • Alopecia areata a non-cicatricial (non- scarring) alopecia, is a relatively common disorder of unknown cause or causes. It is characterized by well defined areas of total hair loss, typically affecting the scalp, although it may extend to effect the entire scalp or even hair follicles on the entire body. Alopecia areata occurs in patients with atopy or Down's syndrome, and usually occurs before age 25. The typical lesions usually appear over a 24 hour period as 3-4 cm asymptomatic smooth bald patches, commonly on the scalp. However, the beard, eyebrows, and/or eyelashes may also be affected. The course of the baldness is variable, and some patients experience regrowth of hair within one year.
  • An alternative therapy is the combination of Psoralen and ultraviolet radiation treatments
  • a wide range of inflammatory disorders can cause hair loss as a result of scarring that produces complete destruction of the pilosebaceous unit.
  • These disorders include discoid lupus erythematosus (DLE) , lichen planopilaris (LPP) , morphea, cicat ⁇ cial pemphigoid, and follicular mucinosis Basal cell carcinoma, infections (e.g., herpes zoster, leprosy) , and physical injury (e.g., burns, radiodermatitis) may also result m scarring and hair loss .
  • DLE discoid lupus erythematosus
  • LPP lichen planopilaris
  • morphea a
  • cicat ⁇ cial pemphigoid e.g., follicular mucinosis Basal cell carcinoma
  • infections e.g., herpes zoster, leprosy
  • physical injury e.g., burn
  • Radiation and chemotherapy treatments for cancers may also cause alopecia, which may be transient or permanent
  • alopecia which may be transient or permanent
  • the loss of hair due to radiation therapy is dose dependent, but usually occurs in the range of 200-800 rads. Follicles in the anagen phase are about 3 times more sensitive to this disruption than are follicles in the telogen phase. Free radicals generated as a result of the cytotoxic mechanisms of action of chemotherapeutic agents and ionizing radiation are thought to have a manor role in the hair loss associated with those modalities of cancer therapy.
  • Cytotoxic drugs may also produce partial or complete inhibition of mitosis or impairment of metabolic processes in the hair matrix, resulting in a thinned, weakened hair shaft This form of alopecia only affects hairs in the anagen phase of growth, and is therefore classified as a type of anagen effluvium. Hair loss due to chemotherapy is most pronounced in the scalp. Other terminal hairs, such as facial or pubic hairs, are variably affected Hair loss is usually first observed 1-2 weeks after initiation of chemotherapy, but becomes progressively more marked 1- 2 months later.
  • U.S. Patent No. 5,030,442 discloses a composition containing minoxidil complexed with an amphipathic compound, oleic acid and with pharmaceutically acceptable excipients which is disclosed as being useful for preparing a non- crystalline minoxidil composition.
  • This patent further discloses that the presence of an amphipathic compound in the minoxidil formulation serves to prevent crystallization of minoxidil on the scalp after application due to evaporation of the ethanol solvent and that preferred amphipathic compounds also improved the transdermal penetration of the drug through the skin.
  • This patent also discloses a minoxidil composition in which the minoxidil is complexed with an amphipathic compound which has a pK of less than about 5 and which contains a single lipophilic chain and a polar head group selected from a sulfate, sulfonate, phosphate, or phosphonate free acid.
  • a pharmaceutical composition for the topical treatment of alopecia which contains, as the active agent, an effective amount of a source of fatty acid or a pharmaceutically acceptable salt or derivative thereof.
  • a method for treating alopecia via the topical administration of a source of fatty acid or a pharmaceutically acceptable salt or derivative thereof, optionally in a pharmaceutically acceptable carrier, to induce regrowth of hair, and/or to prevent further loss of hair.
  • alopecia including androgenetic alopecia, alopecia areata, telogen effluvium, anagen effluvium, and other, non-specific types of hair loss which are caused by oxidative damage .
  • pharmaceutically acceptable salts or complexes refers to salts or complexes that retain the desired biological activity of the source of fatty acids and exhibit minimal undesired toxicological effects.
  • Pharmaceutically acceptable carboxylic acid salts are known to those skilled in the art, including inorganic salts with cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with a cation formed with a nitrogenous base such as ammonia, N,N- dibenzylethylene-diamine, D-glucosamine, or ethylenediamin .
  • Modifications of the active agent can affect its bioavailability and rate of metabolism, thus providing control over the delivery of the agent through the stratum corneum.
  • various modifications of the active molecule such as alteration of charge, can effect water and lipid solubility and thus alter the potential for crossing the stratum corneum.
  • the modifications can affect the bioactivity of the resulting compound, in some cases increasing the activity over the parent compound or increasing the permeability of the parent compound through the stratum corneum. This can easily be assessed by synthesizing the derivative and testing its activity according to the methods described herein, or other methods known to those skilled in the art .
  • the active agent is preferably included in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount of the compound for any of the above conditions without causing serious toxic effects in the patient treated. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.
  • concentration of active agent in a composition of the invention will depend on absorption, distribution, deactivation, and excretion rates of the drug a ⁇ well as other factors known to those skilled in the art. Dosage values will also vary with the severity of the condition to be alleviated.
  • compositions For any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
  • concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient can be administered at once, or can be divided into a number of smaller doses to be administered at varying time intervals .
  • the expression "source of fatty acid” refers to aliphatic carboxylic acids, salts or derivatives thereof, e.g. esters, having chain lengths containing from 3 to 24 carbon atoms.
  • the source of fatty acids provides aliphatic carboxylic acids with chain lengths containing from 14 to 22 carbon atoms.
  • unsaturated fatty acids are preferred, with oleic acid being particularly preferred.
  • Suitable fatty acids which can be used in this invention include, but are not limited to, linoleic, linolenic, lactic, crotonic, isocrotonic, sorbic, cinnamic, maleic, fumaric, lauric, caproic, caprylic, capric, acrylic, pelargonic, neononaoic, neodecanoic, palmitelaidoic, myristic, palmitic, stearic, arachidic, behenic, lignoceric, heptanoic, nonanoic, undecanoic, tridecanoic, pentadecanoic, heptadecanoic, nonadecanoic, henicosanoic, tricosanoic, arachidonic, docosahexanoic, elaidic, erucic, nervonic, palmitoleic, petroselinic, undecylenic, and other saturated and unsatur
  • the active agent or pharmaceutically acceptable salts thereof can, if desired, be mixed with other active materials that do not impair the intended effect, or with materials that supplement the intended effect, such as antioxidants, antibiotics, anti-fungals, anti-inflammatories, disinfectants, or anti-viral compounds.
  • a topical formulation containing an effective amount of a source of fatty acids is administered typically in a compatible solution that can include polymers, suspension agents, ointment, gel or cream vehicle. In certain cases, these vehicles may contain liposomes for creating a reservoir of dissolved agent.
  • a number of animal model assays are available to evaluate the effectiveness of a compound in treating alopecia. Any of these assays can be used to determine the effectiveness of the compounds described herein in treating one or more forms of alopecia. Specifically, the ability of a source of fatty acids to enhance regrowth of hair or to minimize hair loss can be evaluated, for example, by one or more of the following methods :
  • the experiment was carried out according to a block design in which each litter of rat pups was treated as a block.
  • Each block contained seven treatment groups with two pups in each group, except for groups VI and VII which had only one pup per group.
  • the pups were treated with Cytoxan ® , a chemotherapeutic drug, whose side effects include hair loss .
  • the pups were obtained when they were 5 days old.
  • the pups in groups II to V were given a topical treatment of acetone or oleic acid solution.
  • Group I was a healthy control group which was not treated with Cytoxan® (CTX) or oleic acid.
  • Day 1 of the study occurred when the pups were 8 days old.
  • the each pup in Groups II to VII was given a single intraperitoneal injection of Cytoxan ® at a concentration of 30 mg/kg in USP water for injection.
  • the pups in Groups VI and VII were given their first topical treatment with oleic acid on Day 1 of the study, i.e., the first day that Cytoxan ® was administered.
  • Topical treatment with acetone or oleic acid solution was performed once daily on each pup in Groups II to VII for the next 13 days .
  • the pups were videotaped daily to monitor the results of the study.
  • CTX + treatment with acetone starting on the day before CTX was administered was administered.
  • CTX + treatment with 6.0% oleic acid starting on the day before CTX was administered V CTX + treatment with 100% oleic acid brushed into the pups' coat starting on the day before CTX was administered.
  • the pups in Group IV which were treated with 6% oleic acid, retained approximately 40% of the hair on the dorsal area on Day 11 of the study and retained approximately 10% of the hair on the dorsal area at the end of the study.
  • the pups in Group V which were treated with 100% oleic acid, retained approximately 80% of the hair on the dorsal area on Day 11 of the study and retained approximately 40% of the hair on the dorsal area at the end of the study.
  • the pups in Group VI which were treated with 10% oleic acid starting on the same day that the Cytoxan ® was administered, retained approximately 50% of the hair on the dorsal area on Day 11 of the study and retained approximately 40% of the hair on the dorsal area at the end of the study.
  • the pups in Group VII which were treated with 6% oleic acid starting on the same day that the Cytoxan ® was administered, retained approximately 20% of the hair on the dorsal area on Day 11 of the study and had no hair on the dorsal area at the end of the study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Cette invention concerne une composition et un procédé pour traiter, prévenir ou réduire au minimum la perte des cheveux. Ce composé, qui contient une source d'acides gras comme agent actif, est administré topiquement à des patients souffrant de diverses formes d'alopécie.
PCT/US1996/018143 1995-11-13 1996-11-13 Procede pour traiter, prevenir ou minimiser la perte des cheveux au moyen d'une source d'acides gras WO1997017953A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76787/96A AU7678796A (en) 1995-11-13 1996-11-13 Method for the treatment, prevention or minimization of hair loss using a source of fatty acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US661895P 1995-11-13 1995-11-13
US60/006,618 1995-11-13

Publications (1)

Publication Number Publication Date
WO1997017953A1 true WO1997017953A1 (fr) 1997-05-22

Family

ID=21721767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/018143 WO1997017953A1 (fr) 1995-11-13 1996-11-13 Procede pour traiter, prevenir ou minimiser la perte des cheveux au moyen d'une source d'acides gras

Country Status (2)

Country Link
AU (1) AU7678796A (fr)
WO (1) WO1997017953A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002121A1 (fr) * 1997-07-05 1999-01-21 Wella Aktiengesellschaft Agent pour renforcer l'eclat des cheveux
EP1052963A1 (fr) * 1998-02-13 2000-11-22 Carol J. Buck Compositions et traitements destines aux troubles et aux etats associes a la keratine
US6835385B2 (en) 2002-06-14 2004-12-28 Carol J. Buck Compositions and methods for softening, thinning and removing hyperkeratotic tissue
US6858215B2 (en) 2002-06-14 2005-02-22 Carol J. Buck Compositions and methods for softening, thinning and removing hyperkeratotic tissue
WO2006117405A1 (fr) * 2005-05-04 2006-11-09 Coty Prestige Lancaster Group Gmbh Utilisation de piegeurs de radicaux libres dans la protection de la peau et des cheveux et le traitement des dommages causes a la peau et aux cheveux par la chimiotherapie
US20100034904A1 (en) * 2007-03-21 2010-02-11 Giuliani S.P.A. Composition comprisong rutin and polyunsaturated fatty acid having an inhibitory activity on 5-alph reductase
AU2007229399B2 (en) * 2002-06-21 2010-12-23 L'oreal Use of taurine or derivatives thereof for the treatment of alopecia
ITMI20111284A1 (it) * 2011-07-11 2013-01-12 Giovanni Nusca Composizione farmaceutica.
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
CN115054618A (zh) * 2022-08-08 2022-09-16 深圳大学 裂殖壶藻油脂提取物在促进毛发生长或防治脱发中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874791A (en) * 1982-08-10 1989-10-17 Lion Corporation Stimulation of hair growth with aliphatic carboxylic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874791A (en) * 1982-08-10 1989-10-17 Lion Corporation Stimulation of hair growth with aliphatic carboxylic acids

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002121A1 (fr) * 1997-07-05 1999-01-21 Wella Aktiengesellschaft Agent pour renforcer l'eclat des cheveux
EP1052963A1 (fr) * 1998-02-13 2000-11-22 Carol J. Buck Compositions et traitements destines aux troubles et aux etats associes a la keratine
EP1052963A4 (fr) * 1998-02-13 2003-08-06 Carol J Buck Compositions et traitements destines aux troubles et aux etats associes a la keratine
US6835385B2 (en) 2002-06-14 2004-12-28 Carol J. Buck Compositions and methods for softening, thinning and removing hyperkeratotic tissue
US6858215B2 (en) 2002-06-14 2005-02-22 Carol J. Buck Compositions and methods for softening, thinning and removing hyperkeratotic tissue
AU2007229399B2 (en) * 2002-06-21 2010-12-23 L'oreal Use of taurine or derivatives thereof for the treatment of alopecia
WO2006117405A1 (fr) * 2005-05-04 2006-11-09 Coty Prestige Lancaster Group Gmbh Utilisation de piegeurs de radicaux libres dans la protection de la peau et des cheveux et le traitement des dommages causes a la peau et aux cheveux par la chimiotherapie
EA010927B1 (ru) * 2005-05-04 2008-12-30 Коти Престиж Ланкастер Груп Гмбх Использование поглотителей свободных радикалов для защиты и обработки кожи и волос, повреждённых вследствие химиотерапии
US20100034904A1 (en) * 2007-03-21 2010-02-11 Giuliani S.P.A. Composition comprisong rutin and polyunsaturated fatty acid having an inhibitory activity on 5-alph reductase
US9144560B2 (en) * 2007-03-21 2015-09-29 Giuliani S.P.A. Composition comprising rutin and polyunsaturated fatty acid having an inhibitory activity on 5 α-reductase
US8927554B2 (en) 2009-12-15 2015-01-06 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US8871773B2 (en) 2009-12-15 2014-10-28 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US8877762B2 (en) 2009-12-15 2014-11-04 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US9636296B2 (en) 2009-12-15 2017-05-02 Johnson & Johnson Consumer Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US10064811B2 (en) 2009-12-15 2018-09-04 Johnson & Johnson Consumer Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US10646429B2 (en) 2009-12-15 2020-05-12 Johnson & Johnson Consumer Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
WO2013007700A1 (fr) * 2011-07-11 2013-01-17 Nusca Giovanni Composition pharmaceutique comprenant de l'acide oléique, de l'acide palmitique, de l'acide linoléique et de l'acide linolénique
ITMI20111284A1 (it) * 2011-07-11 2013-01-12 Giovanni Nusca Composizione farmaceutica.
CN115054618A (zh) * 2022-08-08 2022-09-16 深圳大学 裂殖壶藻油脂提取物在促进毛发生长或防治脱发中的应用

Also Published As

Publication number Publication date
AU7678796A (en) 1997-06-05

Similar Documents

Publication Publication Date Title
JP3706792B2 (ja) 局所用亜鉛組成物および使用方法
US6048886A (en) Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
EP0667766B1 (fr) Inhibition de la croissance capillaire
DE60308891T2 (de) Neue komplexe von polyhydroxyalkanfettsäureestern und niacinamid
US4372296A (en) Treatment of acne and skin disorders and compositions therefor
US8263054B2 (en) Method of enhancing hair growth
CA1254582A (fr) DERIVES DE PHENYL-.alpha.-ACYLOXYACETAMIDE ET LEUR UTILISATION COMME AGENTS THERAPEUTIQUES
KR100192734B1 (ko) 칼륨 통로 개방제 및 5알파-환원효소 억제제를 사용하는 모발 성장의 자극 방법
JP2001521901A (ja) 皮膚の光損傷の処置および予防のための抗変異誘発組成物
KR20120099454A (ko) 모발 성장을 촉진하기 위한 조성물 및 방법
WO1997017953A1 (fr) Procede pour traiter, prevenir ou minimiser la perte des cheveux au moyen d'une source d'acides gras
JPS6345212A (ja) 改善された浸透性局所用医薬組成物
EP2431031B1 (fr) Composition pour prévenir la perte de cheveux ou stimuler la pousse des cheveux
US20190343835A1 (en) Hair loss treatment composition and method
US20030194446A1 (en) Zinc oxide compositions for dermatheraputics
US20140199413A1 (en) Melatonin and an antimicrobial or antibacterial agent for the treatment of acne
WO1995034303A1 (fr) Procede pour traiter, prevenir ou reduire au minimum la chute des cheveux
US20050163811A1 (en) Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
DE69931487T2 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
KR20080005525A (ko) 습진 치료를 위한 옥사프로진 또는 밀접관련 화합물
US4034114A (en) Treatment of skin keratoses with retinal
WO1990009792A1 (fr) Application locale d'amiloride ou de ses analogues dans le traitement d'inflammations
CA2220687A1 (fr) Utilisation d'un derive oxalate pharmaceutiquement acceptable dans la fabrication d'un medicament pour le traitement d'affections cutanees
WO2018202028A1 (fr) Utilisation d'une composition dans la préparation d'un médicament pour stimuler la croissance des cheveux individuels, prévenir la chute des cheveux, ou stimuler la production des cellules souches des follicules pileux individuels
WO2020028745A1 (fr) Procédés de réduction de formation de cicatrice anormale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase